Posted by Michael Wonder on 15 Sep 2021
Lilly to supply 388,000 doses of etesevimab to U.S. Government for treatment of COVID-19
15 September 2021 - Additional doses of etesevimab will be paired with existing bamlanivimab purchased by the U.S. Government
Eli Lilly today announced an additional purchase by the U.S. Government for its neutralising antibody therapies authorised for emergency use as a treatment for COVID-19.
As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship Q3 2021 and the remaining to be shipped in Q4. This transaction is expected to generate approximately $330 million in revenue in the second half of 2021.
